Kingsdown v. Hollister: Gross Negligence Is Not Intent to Deceive

Kingsdown Medical Consultants, Ltd. v. Hollister Inc., 863 F.2d 867 (Fed. Cir. 1988), is the decision that pulled inequitable conduct back from the brink. Decided December 21, 1988, with Chief Judge Markey writing and the court sitting en banc on the crucial intent question, the opinion held that gross negligence in patent prosecution does not, standing alone, establish the intent to deceive that the inequitable conduct defense demands. That holding rescued the ordinary clerical mistakes of prosecution from becoming automatic patent-killers and set the intent standard that governed the doctrine for the next two decades, until the Federal Circuit revisited inequitable conduct en banc in Therasense in 2011.

The stakes of the defense are extreme. A finding of inequitable conduct renders every claim of a patent unenforceable, no matter how meritorious, and it can spill over to related patents and expose counsel to professional consequences. By the late 1980s the Federal Circuit had watched the defense metastasize into what a panel had called, months earlier in Burlington Industries, Inc. v. Dayco Corp., 849 F.2d 1418 (Fed. Cir. 1988), an absolute plague, pleaded in almost every major patent case and often resting on nothing more than an attorney’s carelessness. Kingsdown quoted that description in a footnote. Kingsdown was the court’s attempt to discipline it.

At a glance

• Case: Kingsdown Medical Consultants, Ltd. v. Hollister Inc., 863 F.2d 867 (Fed. Cir. 1988)
• Decided: December 21, 1988, United States Court of Appeals for the Federal Circuit, en banc as to the intent standard, opinion by Chief Judge Markey
• Holding: Gross negligence does not of itself justify an inference of intent to deceive; the conduct viewed in its entirety must manifest a sufficiently culpable state of mind.
• Significance: The cornerstone intent standard for inequitable conduct, later built upon by Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed. Cir. 2011) (en banc).

The duty of candor and its enforcement

Patent prosecution is largely ex parte. The applicant and the examiner interact without an adversary in the room, so the system depends on the applicant’s duty of candor and good faith, codified in 37 C.F.R. Section 1.56. When that duty is breached by a material misrepresentation or omission made with intent to deceive, courts may declare the resulting patent unenforceable under the equitable doctrine of inequitable conduct. The defense has two elements, materiality and intent, and historically courts balanced them on a sliding scale, so that a highly material omission could support a finding of intent on relatively thin evidence.

That sliding scale was the problem. If gross negligence in handling a material reference could be enough to infer deceptive intent, then any prosecutor who made a serious mistake risked having the entire patent destroyed. The doctrine threatened to convert malpractice into fraud, and it gave accused infringers a cheap, scorched-earth defense to raise in discovery.

The clerical error at the center of the case

The patent in suit, U.S. Patent No. 4,460,363, covered a two-piece ostomy appliance, a medical device for patients with abdominal openings that discharge waste. The alleged misconduct was not a hidden prior-art reference or a fabricated test result. It was a mistake in claim handling. During prosecution the attorney was working with two versions of a claim numbered 50, an original claim 50 that had been rejected and an amended claim 50. In assembling a continuation and telling the examiner which claims corresponded to previously allowed subject matter, the attorney identified the wrong version, effectively representing that the rejected form of claim 50 had been allowed when it was the amended form that had cleared.

Hollister seized on that error, arguing that the mistake was so serious, and the competitive stakes so obvious, that it amounted to inequitable conduct rendering the whole patent unenforceable. The district court agreed, finding intent to deceive and holding the patent unenforceable. The Federal Circuit reversed.

The en banc holding on intent

Writing for the court, Chief Judge Markey drew a firm line. Gross negligence, the court held, does not of itself justify an inference of intent to deceive. To find the deceptive intent that inequitable conduct requires, a court must look at the involved conduct in its entirety and determine that it indicates a sufficiently culpable state of mind. A blunder, even a grossly negligent one, is not the same as a decision to deceive the Patent and Trademark Office, and treating it as such would unfairly brand honest practitioners as fraudsters and would destroy patents for reasons unrelated to their validity.

The court examined the record and concluded that the district court’s finding of intent was clearly erroneous. Nothing in the evidence showed that the attorney chose the wrong claim in order to mislead the examiner, as opposed to simply making an error while juggling two similarly numbered claims. Because deceptive intent had not been proven, the inequitable conduct holding could not stand, and the court reversed and remanded. In doing so, the en banc court disapproved language in prior opinions that had suggested gross negligence could supply the requisite intent, tightening a doctrine that had drifted.

From Kingsdown to Therasense

Kingsdown set the intent floor, but the defense kept expanding, and by 2011 the Federal Circuit returned to the problem en banc in Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed. Cir. 2011). Therasense went further than Kingsdown in two ways. On intent, it held that the accused infringer must prove that the specific intent to deceive is the single most reasonable inference to be drawn from the evidence, rejecting the sliding scale that had let strong materiality lower the intent bar. On materiality, it generally required but-for materiality, meaning the Patent and Trademark Office would not have allowed the claim had it known the truth. Therasense is often described as reforming inequitable conduct, but its intent holding is Kingsdown’s principle carried to its conclusion. The idea that carelessness is not deceit runs straight through both decisions.

Open questions

Even after Therasense, hard questions remain about how Kingsdown’s teaching applies at the margins. The line between gross negligence and a deliberate decision to look the other way, sometimes framed as deliberate indifference or willful blindness, is not always crisp, and litigants still fight over when a pattern of careless conduct crosses into inferable intent. Therasense recognized an exception to but-for materiality for affirmative egregious misconduct, and the scope of that exception, and whether intent can be inferred more readily in such cases, continues to generate disputes. Finally, the practical burden of proving state of mind through circumstantial evidence means that reasonable inferences about intent remain a recurring battleground even under the tightened standard.

Implications for inventors and businesses

• Careless mistakes are survivable. Kingsdown means an honest clerical error in prosecution, without proof of deceptive intent, will not by itself render a patent unenforceable, which protects the value of patents that emerged from imperfect but good-faith prosecution.
• Document good faith in real time. Because intent is inferred from the whole record, prosecutors should keep clear records of decisions about references and claims, so that a later accusation of deceit can be met with contemporaneous evidence of ordinary care.
• Do not weaponize every prosecution slip. Litigants considering an inequitable conduct defense should recognize that after Kingsdown and Therasense they must prove specific intent to deceive, not merely negligence, and a thin theory can draw sanctions.
• Candor still governs. The duty under 37 C.F.R. Section 1.56 remains real, and the safest course is full disclosure of material prior art, because the defense that Kingsdown narrowed was never abolished.

Frequently asked questions

What is inequitable conduct in patent law? Inequitable conduct is an equitable defense that renders an entire patent unenforceable when the applicant, during prosecution, breached the duty of candor to the Patent and Trademark Office by misrepresenting or withholding material information with an intent to deceive. Because the penalty reaches every claim, courts treat it as a severe remedy.

What did Kingsdown change about proving deceptive intent? Kingsdown held that gross negligence does not, by itself, justify an inference of intent to deceive the Patent and Trademark Office. The accused party’s conduct, viewed in light of all the evidence, must indicate a sufficiently culpable state of mind, so a careless mistake in prosecution is not enough to invalidate a patent for inequitable conduct.

Is Kingsdown still good law after Therasense? Yes. Therasense v. Becton, Dickinson tightened the standard further in 2011 by requiring specific intent to deceive as the single most reasonable inference and by narrowing materiality to but-for materiality. Therasense built on Kingsdown’s core teaching rather than displacing it, so Kingsdown remains the foundational intent case.

Authorities and sources

• Kingsdown Medical Consultants, Ltd. v. Hollister Inc., 863 F.2d 867 (Fed. Cir. 1988) (Justia)
• Kingsdown Medical Consultants, Ltd. v. Hollister Inc. (Google Scholar)
• Kingsdown Medical Consultants, Ltd. v. Hollister Inc. case brief (Quimbee)
• 37 C.F.R. Section 1.56, Duty to disclose information material to patentability (Cornell LII)
• Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed. Cir. 2011) (en banc) (CourtListener)
• IPWatchdog, “Inequitable Conduct Lives: Patent Practitioners Beware”